Table 3.
Univariate Analysis of Factors Related to Mortality
| Outcome | Survivors (n = 153) | Died (n = 15) | p Value |
|---|---|---|---|
| Preoperative variables | |||
| Age | 64 [53, 72] | 69 [58, 74] | 0.23 |
| Male | 66 (43.1%) | 6 (40.0%) | 0.81 |
| Cerebrovascular disease | 22 (14.4%) | 5 (33.3%) | 0.069 |
| Diabetes mellitus | 32 (20.9%) | 3 (20.0%) | 1.0000 |
| Endocarditis | 23 (15.0%) | 2 (13.3%) | 1.0000 |
| Peripheral vascular disease | 16 (10.5%) | 4 (26.7%) | 0.084 |
| Renal failure | 25 (16.3%) | 11 (73.3%) | < 0.0001 |
| Renal failure (hemodialysis) | 9 (5.9%) | 2 (13.3%) | 0.26 |
| Tobacco use | 70 (45.8%) | 9 (60.0%) | 0.29 |
| Congestive heart failure | 105 (68.6%) | 12 (80.0%) | 0.56 |
| Myocardial infarction | 26 (17.0%) | 5 (33.3%) | 0.16 |
| Ejection fraction (%) | 55 [40, 60] | 58 [55, 60] | 0.29 |
| MELD score ≥ 15 | 17 (11.1%) | 7 (46.7%) | 0.0017 |
| Intraoperative variables | |||
| Concomitant operations | 129 (84.3%) | 15 (100%) | 0.13 |
| Concomitant CABG | 30 (19.6%) | 2 (13.3%) | 0.74 |
| Concomitant mitral valve procedure | 99 (64.7%) | 9 (60.0%) | 0.72 |
| Concomitant AVR | 38 (24.8%) | 6 (40.0%) | 0.22 |
| Tricuspid valve replacement | 12 (7.8%) | 0 (0.0%) | 0.60 |
| Cardiopulmonary bypass time (min) | 145 [109, 185] | 150 [129, 225] | 0.12 |
AVR = aortic valve replacement; CABG = coronary artery bypass graft surgery; MELD = Model for End-Stage Liver Disease.